FIGURE 6.
Inhibiting USP22 expression enhanced cisplatin sensitivity in cisplatin-resistant A549/CDDP cell nude mouse xenografts. (A) Representative figures and growth curve of tumor by subcutaneous injection of A549/CDDP and A549/CDDP-sh-USP22 cells. (B) IHC staining of Sirt1, γH2AX and Ki67 in tumor nodules from A549/CDDP and A549/CDDP-sh-USP22 cells derived xenografts. Bar: 200 μm. (C) Western blot analysis of USP22, Sirt1, γH2AX, Ubi-H2A, and Ki67 in A549/CDDP and A549/CDDP-sh-USP22 cells derived xenografts. Every experiment was conducted at least three times, and the average is shown (mean ± SD). ∗P < 0.05, ∗∗P < 0.01, significant.